Indaptus Therapeutics Inc
Change company Symbol lookup
Select an option...
INDP Indaptus Therapeutics Inc
FUSN Fusion Pharmaceuticals Inc
RDUS Schnitzer Steel Industries Inc
ALEC Alector Inc
LZM Lifezone Metals Ltd
LMRMF Lomiko Metals Inc
SOXL Direxion Daily Semiconductor Bull 3X Shares
OXSQ Oxford Square Capital Corp
BAER Bridger Aerospace Group Holdings Inc
CMRA Comera Life Sciences Holdings Inc

Health Care : Biotechnology |
Company profile

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The Company is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. It designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, through pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs), in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.


Last Trade
0.04 (1.61%)
B/A Size

Market Hours

Closing Price
Day's Change
-0.22 (-8.12%)
Bid close
Ask close
B/A Size
Day's High
Day's Low

10-day average volume:

Dell stock rises as analyst upgrades after calling bottom to PC market

10:12 am ET May 2, 2023 (MarketWatch)

By Wallace Witkowski

Morgan Stanley upgrades PC maker to overweight, hikes price target to $55

Dell Technologies Inc. shares rose Tuesday after Morgan Stanley upgraded the PC maker and called a March-ending quarter bottom in the sector still reeling from inventory issues.

Dell (DELL) shares rose as much as 4% in morning trading to an intraday high of $45.65. That puts shares up 13% year to date, compared with an 8% gain in the S&P 500 index and a 16% rise in the tech-heavy Nasdaq Composite Index .

Woodring upgraded Dell to overweight from equal weight and raised his price target to $55 from $45, forecasting that the PC market bottomed in March-ending quarter.

"The worst of the PC downcycle is likely behind us, and we expect Dell to outperform alongside the rebound in the PC market, similar to past PC cycles," Woodring said.

"More so than any other name in our coverage, Dell's management has been ultra-conservative in guiding [fiscal year 2024], which limits negative earnings revisions risk," the Morgan Stanley analyst noted. Analysts surveyed by FactSet expect fiscal 2024 earnings of $5.30 a share on revenue of $87.13 billion.

"We believe management is hyper-focused on accelerating shareholder returns, which our analysis shows increases the odds of outperformance vs. peers," the analyst added.

Of the 20 analysts surveyed by FactSet that cover Dell, 13 had buy ratings, while seven had hold ratings, along with a price target of $45.09.

-Wallace Witkowski

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

May 02, 2023 10:12 ET (14:12 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.